1626

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → [+]

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/856,009
Filing Date	May 16, 2001
First Named Inventor	Kozak et al.
Group Art Unit	2594
Examiner Name	Sonya N. Wright
Total Number of Pages in This Submission	33
Attorney Docket Number	800.1012

ENCLOSURES *(check all that apply)*

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☒ Amendment / Response
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☐ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/ Incomplete Application
  - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Assignment Papers *(for an Application)*
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) ____
- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group *(Appeal Notice, Brief, Reply Brief)*
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) *(please identify below)*:
  - **- return receipt postcard**

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Name	Davidson, Davidson & Kappel, LLC				
Address	485 Seventh Avenue, 14th Floor				
City	New York	State	NY	Zip Code	10018
Country	USA	Telephone	(212) 736-1940	Fax	(212) 736-2427

Individual name	Morey B. Wildes
Signature	Morey B. Wildes
Date	February 26, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: February 26, 2003

Typed or printed name	Morey B. Wildes		
Signature	Morey B. Wildes	Date	February 26, 2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	KOZAK, et al.
Serial No.:	09/856,009
Filed:	May 16, 2001
For:	**PHOSPHOLIPID DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS**
Examiner:	Sonya N. Wright (Group Art Unit: 1626)

Box: NON-FEE AMENDMENT
Commissioner for Patents
Washington, D.C. 20231

February 26, 2003

SUPPLEMENTAL PRELIMINARY AMENDMENT

S I R:

Preliminary to examination, please amend the above-identification as follows:

IN THE SPECIFICATION

Please replace the paragraph beginning at page 2, line 29 with the following rewritten paragraph:

Diclofenac ([o-[(2,6-dichlorophenyl)amino]phenyl]acetate) is a non-steroidal anti-inflammatory drug of the phenylacetic acid class. When given orally the absorption of diclofenac is rapid and complete. It binds extensively to plasma albumin. Substantial concentrations of drug are attained in synovial fluid, which is the proposed site of action of the NSAIDs. Diclofenac is a potent inhibitor of prostaglandin synthesis and has also been shown to inhibit interleukin-1 (IL-1β) and tumor necrosis factor alpha (TNF-α), involved in osteoarthritis. Gastrointestinal complications such as ulceration and intolerance are the most common adverse effect of diclofenac. Renal dysfunction and hypersensitivity reactions also occur. Many patients with